Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 3/20 | 0.41 |
| ▸ | CD274 | Q9NZQ7 | 3/20 | 0.40 |
| ▸ | PDCD1LG2 | Q9BQ51 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 4/20 | 0.39 |
| ▸ | CA1 | P00915 | 3/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | VSIR | Q9H7M9 | 3/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | SDCBP | O00560 | 1/20 | 0.35 |
| ▸ | SDC2 | P34741 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1997636 | 1.00 | MME (0.41) | MMECD274PDCD1LG2CA2CA1 | |
| SCHEMBL1997638 | 1.00 | MME (0.41) | MMECD274PDCD1LG2CA2CA1 | |
| SCHEMBL6314356 | 0.84 | NPSR1 (0.50) | NPSR1ALDH1A1SDCBPSDC2SMN1; SMN2 | |
| SCHEMBL15231611 | 0.84 | NPSR1 (0.50) | NPSR1ALDH1A1SDCBPSDC2SMN1; SMN2 | |
| SCHEMBL4195957 | 0.83 | CYP2C9 (0.43) | MMECD274PDCD1LG2CA2CA1 | |
| SCHEMBL4195960 | 0.83 | CYP2C9 (0.43) | MMECD274PDCD1LG2CA2CA1 | |
| SCHEMBL6308358 | 0.83 | MME (0.41) | MMECD274PDCD1LG2CA2CA1 | |
| SCHEMBL23408858 | 0.81 | CA2 (0.41) | MMECD274PDCD1LG2CA2CA1 | |
| SCHEMBL11106438 | 0.81 | CA2 (0.41) | MMECD274PDCD1LG2CA2CA1 | |
| SCHEMBL3868722 | 0.81 | CA2 (0.41) | MMECD274PDCD1LG2CA2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104583235-B | Antibodies comprising site-specific unnatural amino acid residues, methods of making and using the same | 苏特罗生物制药公司 | 2019-03-01 | — | — | CN | disclosed |
| EP-0996455-B1 | ALPHA-O-LINKED GLYCOCONJUGATES WITH CLUSTERED (2,6)-ST EPITOPES, METHODS OF PREPARATION AND USES THEREOF | SLOAN KETTERING INST CANCER (US) | 2009-12-16 | — | — | EP | disclosed |
| US-7550146-B2 | Glycopeptide conjugates and uses thereof | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2009-06-23 | — | — | US | disclosed |
| US-7160856-B2 | α-O-linked glycoconjugates, methods of preparation and uses thereof | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2007-01-09 | — | — | US | disclosed |
| US-20050222398-A1 | Glycopeptide conjugates and uses thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-10-06 | — | — | US | disclosed |
| EP-0996455-A4 | ALPHA-O-LINKED GLYCOCONJUGATES WITH CLUSTERED (2,6)-ST EPITOPES, METHODS OF PREPARATION AND USES THEREOF | SLOAN KETTERING INSTITUTEFOR C (US) | 2005-06-08 | — | — | EP | disclosed |
| EP-1091751-A4 | TRIMERIC ANTIGENIC O-LINKED GLYCOPEPTIDE CONJUGATES, METHODS OF PREPARATION AND USES THEREOF | SLOAN KETTERING INSTITUTEFOR C (US) | 2005-01-19 | — | — | EP | disclosed |
| US-20040102607-A1 | Trimeric antigenic O-linked glycopeptide conjugates, methods of preparation and uses thereof | DANISHEFSKY SAMUEL J (US) | 2004-05-27 | — | — | US | disclosed |
| US-6660714-B1 | Anticancer agents | SLOAN KETTERING INSTITUTE FOR CANCER RESEARCH | 2003-12-09 | — | — | US | disclosed |
| EP-1091751-A1 | TRIMERIC ANTIGENIC O-LINKED GLYCOPEPTIDE CONJUGATES, METHODS OF PREPARATION AND USES THEREOF | Sloan-Kettering Institute For Cancer Research (US) | 2001-04-18 | — | — | EP | disclosed |
| EP-0996455-A1 | $g(a)-O-LINKED GLYCOCONJUGATES WITH CLUSTERED (2,6)-ST EPITOPES, METHODS OF PREPARATION AND USES THEREOF | Sloan-Kettering Institute For Cancer Research (US) | 2000-05-03 | — | — | EP | disclosed |
| WO-1999048515-A9 | TRIMERIC ANTIGENIC O-LINKED GLYCOPEPTIDE CONJUGATES, METHODS OF PREPARATION AND USES THEREOF | SLOAN KETTERING INST CANCER (US) | 1999-11-25 | — | — | WO | disclosed |
| WO-1999048515-A1 | TRIMERIC ANTIGENIC O-LINKED GLYCOPEPTIDE CONJUGATES, METHODS OF PREPARATION AND USES THEREOF | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 1999-09-30 | — | — | WO | disclosed |
| WO-1998046246-A1 | α-O-LINKED GLYCOCONJUGATES WITH CLUSTERED (2,6)-ST EPITOPES, METHODS OF PREPARATION AND USES THEREOF | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 1998-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222398-A1 | Glycopeptide conjugates and uses thereof | MUC1, FUT5, FUT6 | MME 1029/4885CD274 2928/4885PDCD1LG2 3102/4885 |
| US-20040102607-A1 | Trimeric antigenic O-linked glycopeptide conjugates, methods of preparation and uses thereof | MUC1, OSTC, SIGLEC7 | MME 1210/4885CD274 715/4885PDCD1LG2 716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.